Kracer SB, Alduncin LN

Idioma: Español
Referencias bibliográficas: 33
Paginas: 355-367
Archivo PDF: 89.86 Kb.

RESUMEN

El ácido acetilsalicílico es el antiinflamatorio y analgésico-antipirético más prescrito y constituye el compuesto estándar en la comparación y evaluación de otros productos. Tiene efecto antiplaquetario y está en estudio de comprobación su efecto antioxidante. Su actividad antiinflamatoria se ha relacionado con reducción del riesgo de padecer ciertos cánceres y enfermedades neurodegenerativas. Está demostrada su utilidad en la prevención de enfermedades cardiovasculares, previa valoración del riesgo-beneficio en forma individual. Sus efectos adversos son relevantes y limitan su uso. En la actualidad se dispone de nuevos compuestos menos tóxicos y con actividad más selectiva. Este artículo revisa las aplicaciones terapéuticas y los efectos adversos del ácido acetilsalicílico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Goodman Gilman A, Ruddon R, Molinoff P, et al. Las bases farmacológicas de la terapéutica. 9ª ed. México: McGraw-Hill Interamericana, 1996;pp:661-76.

2. Awtry E, Loscalzo JA. Aspirin. Circulation 2000;101(10):1206-18.

3. Vane J. Aspirin and other anti-inflammatory drugs. Thorax 2000;55(Suppl 2):S3-S9.

4. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflamatory drugs. N Engl J Med 1999;340:1888-98.

5. Suresh B, Sundeep S. Aspirin and asthma. Chest 2000;118(5):1470-6.

6. Jordan S, White J. Nonsteroidal antiinflamatory drugs: clinical issues. Nurs Stand 2001;15(23):45-54.

7. Weisman S, Graham D. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197-202.

8. Lauer M. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346(19):1468-74.

9. Eidelman R, Hebert P, Weisman S, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.

10. Bhatt D, Chew D, Hirsch A, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-8.

11. Lefkovits J, Plow E, Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332(23):1553-9.

12. Boltri J, Akerson M, Vogel R. Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systemic review of all-cause mortality. J Fam Pract 2002;51(8):700-4.

13. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336(12):847-60.

14. Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501.

15. Golzari H, Cebul R, Bahler R. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125(4):311-23.

16. Taylor F, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.

17. He J, Whelton P, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280(22):1930-5.

18. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1883-7.

19. Shris P, Cannon C, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129(5):394-405.

20. Gorelick P, Born G, D’Agostino R, et al. Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. Stroke 1999;30(8):1716-21.

21. Rauch U, Osende J, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-38.

22. Plaisance K, Mackowiak P. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med 2000;160(4):449-56.

23. Kowalski M. Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different? Thorax 2000;55(Suppl 2):S84-S86.

24. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.

25. Chow E, Cherry J, Harrison R, et al. Reassessing Reye syndrome. Arch Pediatr Adolesc Med 2003;157:1241-2.

26. Glasgow JFT, Middleton B. Reye syndrome: insights on causation and prognosis. Arch Dis Child 2001;85:351-3.

27. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for preventions of pre-eclampsia and its consequences: systematic review. BMJ 2001;322(7282):329-33.

28. Etminan M, Gill S, Samii A. Effect of nonsteroidal antiinflamatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:327-30.

29. Schiess M. Nonsteroidal antiinflamatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch Neurol 2003;60:1043-4.

30. Paterson JR, Lawrence JR. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. QJM 2001;94(8):445-8.

31. Chan EL, Giovannucci ES, Schernhammer GA, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140:157-66.

32. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost effectiveness analysis. Ann Intern Med 2001;136:769-81.

33. Basler JW, Piazza GA. Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective inhibitors of prostate cancer chemoprevention. J Urol 2004;171:S59-S63.